The Governing Council of Castile-La Mancha has authorized a contract for the supply of monoclonal antibodies against diseases caused by respiratory syncytial virus (RSV) for the immunization of newborns and infants in Castile-La Mancha for the 2023-2024 season. ., in the amount of 3,260,400 euros.
Esther Padilla, spokesman for the Castile-Latin Executive, explained that respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in children under one year of age, especially those associated with bronchiolitis and pneumonia, and in children. adults over 65 years of age and in persons at risk.
For this reason, Padilla insisted that “the priority is the prevention of diseases, the health of all citizens”, as well as reducing the significant overload that occurs every winter in primary care services and hospitals.
On October 31, 2022, the European Commission authorized Beyfortus for the prevention of lower respiratory illness caused by RSV in newborns and infants during the first season of exposure to the virus.
In adults and older children, respiratory syncytial virus infection may be asymptomatic or manifest as sinusitis or the common cold. Infants may also experience irritability, difficulty breathing, and reduced activity.
